Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Monday, AnalystRatings.com reports. They presently have a $15.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 324.93% from the stock’s current price.
Other equities analysts also recently issued research reports about the company. Cowen reaffirmed a “buy” rating on shares of Kezar Life Sciences in a research report on Thursday, August 8th. Zacks Investment Research downgraded Kezar Life Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 9th. Finally, ValuEngine raised Kezar Life Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Kezar Life Sciences presently has a consensus rating of “Buy” and an average price target of $9.25.
NASDAQ:KZR opened at $3.53 on Monday. Kezar Life Sciences has a twelve month low of $2.82 and a twelve month high of $36.33. The company has a quick ratio of 20.32, a current ratio of 20.32 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average price of $3.36 and a two-hundred day moving average price of $9.59. The company has a market cap of $70.62 million, a P/E ratio of -1.56 and a beta of 0.86.
Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. As a group, analysts anticipate that Kezar Life Sciences will post -1.96 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in KZR. Marshall Wace LLP acquired a new stake in shares of Kezar Life Sciences in the 1st quarter valued at approximately $704,000. MetLife Investment Advisors LLC bought a new stake in Kezar Life Sciences in the 1st quarter valued at $123,000. Metropolitan Life Insurance Co NY bought a new stake in Kezar Life Sciences in the 1st quarter valued at $89,000. Ironsides Asset Advisors LLC raised its stake in Kezar Life Sciences by 50.0% in the 2nd quarter. Ironsides Asset Advisors LLC now owns 17,650 shares of the company’s stock valued at $136,000 after acquiring an additional 5,886 shares during the period. Finally, Wells Fargo & Company MN raised its stake in Kezar Life Sciences by 302.5% in the 2nd quarter. Wells Fargo & Company MN now owns 30,878 shares of the company’s stock valued at $238,000 after acquiring an additional 23,207 shares during the period. 52.27% of the stock is owned by institutional investors.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
Recommended Story: What is the price-sales ratio?
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.